BR112016029619A2 - novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas - Google Patents

novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas

Info

Publication number
BR112016029619A2
BR112016029619A2 BR112016029619A BR112016029619A BR112016029619A2 BR 112016029619 A2 BR112016029619 A2 BR 112016029619A2 BR 112016029619 A BR112016029619 A BR 112016029619A BR 112016029619 A BR112016029619 A BR 112016029619A BR 112016029619 A2 BR112016029619 A2 BR 112016029619A2
Authority
BR
Brazil
Prior art keywords
bacterial infections
treating bacterial
fluoroquinolones
novel
novel fluoroquinolones
Prior art date
Application number
BR112016029619A
Other languages
English (en)
Other versions
BR112016029619B1 (pt
BR112016029619A8 (pt
Inventor
Aubry Alexandra
Anquetin Guillaume
Original Assignee
Univ Pierre Et Marie Curie Paris 6 Upmc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pierre Et Marie Curie Paris 6 Upmc filed Critical Univ Pierre Et Marie Curie Paris 6 Upmc
Publication of BR112016029619A2 publication Critical patent/BR112016029619A2/pt
Publication of BR112016029619A8 publication Critical patent/BR112016029619A8/pt
Publication of BR112016029619B1 publication Critical patent/BR112016029619B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a novas fluoroquinolonas, composições farmacêuticas ou medicamentos que as contêm e à sua utilização para o tratamento de uma infecção bacteriana.
BR112016029619-2A 2014-06-18 2015-06-18 Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos BR112016029619B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14173040.8A EP2957561A1 (en) 2014-06-18 2014-06-18 Novel fluoroquinolones and use thereof to treat bacterial infections
EP14173040.8 2014-06-18
PCT/EP2015/063752 WO2015193454A1 (en) 2014-06-18 2015-06-18 Novel fluoroquinolones and use thereof to treat bacterial infections

Publications (3)

Publication Number Publication Date
BR112016029619A2 true BR112016029619A2 (pt) 2017-08-22
BR112016029619A8 BR112016029619A8 (pt) 2022-10-18
BR112016029619B1 BR112016029619B1 (pt) 2022-11-16

Family

ID=50972561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029619-2A BR112016029619B1 (pt) 2014-06-18 2015-06-18 Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos

Country Status (10)

Country Link
US (1) US10087165B2 (pt)
EP (2) EP2957561A1 (pt)
CN (1) CN106660990B (pt)
BR (1) BR112016029619B1 (pt)
CA (1) CA2952300C (pt)
ES (1) ES2769827T3 (pt)
PL (1) PL3157911T3 (pt)
RU (1) RU2723545C2 (pt)
WO (1) WO2015193454A1 (pt)
ZA (1) ZA201608607B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2636751C1 (ru) * 2016-11-02 2017-12-01 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Антибактериальные средства на основе производных ципрофлоксацина
CN110563645B (zh) * 2019-06-14 2021-03-30 山东省联合农药工业有限公司 一种喹诺酮类化合物及其制备方法和应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033157A1 (de) 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3248505A1 (de) * 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7(4- (oxoalkyl)-1-piperazinyl/-3-chinolincarbonsaeuren und ihre derivate, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3248507A1 (de) * 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen Mikrobizide mittel auf chinoloncarbonsaeure basis
DE3306771A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
CN1014410B (zh) * 1984-06-04 1991-10-23 拜尔股份公司 制备7-(3-取代-1-哌嗪基)-3-喹诺酮羧酸的方法
DE3542002A1 (de) * 1985-11-28 1987-06-04 Bayer Ag 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
MY105136A (en) * 1988-04-27 1994-08-30 Daiichi Seiyaku Co Optically active pyridonecarboxylic acid derivatives.
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
CN100341855C (zh) * 2005-02-22 2007-10-10 南京澳新医药科技有限公司 7－取代－8－甲氧基氟喹诺酮羧酸衍生物、制法、制剂及其用途

Also Published As

Publication number Publication date
CN106660990A (zh) 2017-05-10
RU2723545C2 (ru) 2020-06-16
CA2952300A1 (en) 2015-12-23
EP3157911B1 (en) 2019-12-04
US20170144992A1 (en) 2017-05-25
BR112016029619B1 (pt) 2022-11-16
US10087165B2 (en) 2018-10-02
ZA201608607B (en) 2020-05-27
RU2017100506A (ru) 2018-07-20
BR112016029619A8 (pt) 2022-10-18
PL3157911T3 (pl) 2020-07-13
EP3157911A1 (en) 2017-04-26
EP2957561A1 (en) 2015-12-23
CA2952300C (en) 2022-06-28
WO2015193454A1 (en) 2015-12-23
CN106660990B (zh) 2019-10-18
ES2769827T3 (es) 2020-06-29
RU2017100506A3 (pt) 2019-01-30

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112015027699A2 (pt) Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CO2017001658A2 (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
EA202090683A2 (ru) Способы и композиции для лечения рака
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SORBONNE UNIVERSITE (FR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2015, OBSERVADAS AS CONDICOES LEGAIS